Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) Shorted Shares Increased By 97.12%

The stock of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) registered an increase of 97.12% in short interest. CRNX’s total short interest was 862,800 shares in December as published by FINRA. Its up 97.12% from 437,700 shares, reported previously. With 133,400 shares average volume, it will take short sellers 7 days to cover their CRNX’s short positions. The short interest to Crinetics Pharmaceuticals Inc’s float is 53.08%.

The stock increased 1.64% or $0.56 during the last trading session, reaching $34.79. About 27,721 shares traded. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) has 0.00% since December 7, 2017 and is . It has underperformed by 15.62% the S&P500.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. The company has market cap of $836.25 million. The Company’s lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. It currently has negative earnings. The firm is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors.

More notable recent Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) news were published by: Benzinga.com which released: “The Week Ahead: Best Buy, Lululemon Look To Extend Retail’s Rally – Benzinga” on August 27, 2018, also Nasdaq.com with their article: “Rare endocrine disease biotech Crinetics Pharmaceuticals files for a $86 million IPO – Nasdaq” published on June 22, 2018, Globenewswire.com published: “Crinetics Pharmaceuticals Announces Pricing of Initial Public Offering – GlobeNewswire” on July 17, 2018. More interesting news about Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) were released by: Marketwatch.com and their article: “Crinetics Pharmaceuticals stock surges 24% in trading debut – MarketWatch” published on July 18, 2018 as well as Globenewswire.com‘s news article titled: “Crinetics Pharmaceuticals Appoints Marc Wilson as Chief Financial Officer – GlobeNewswire” with publication date: January 04, 2018.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.